Page last updated: 2024-10-16

adenine and Cancer of Lung

adenine has been researched along with Cancer of Lung in 78 studies

Research Excerpts

ExcerptRelevanceReference
"Pemetrexed, a multitarget antifolate used to treat malignant mesothelioma and non-small cell lung cancer (NSCLC), has been shown to stimulate autophagy."7.81Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells. ( Cha, BK; Hwang, KE; Jeong, ET; Jung, JW; Kim, HR; Kim, YS; Kwon, SJ; Oh, SH; Park, DS; Yoon, KH, 2015)
"Chronic lung inflammation is accepted as being associated with the development of lung cancer caused by nickel exposure."3.83Upregulation of SQSTM1/p62 contributes to nickel-induced malignant transformation of human bronchial epithelial cells. ( Che, X; Chen, LC; Gao, J; Gu, J; Huang, C; Huang, H; Jin, H; Li, J; Li, Y; Lyu, J; Xie, Q; Zhang, L; Zhu, J, 2016)
"Pemetrexed, a multitarget antifolate used to treat malignant mesothelioma and non-small cell lung cancer (NSCLC), has been shown to stimulate autophagy."3.81Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells. ( Cha, BK; Hwang, KE; Jeong, ET; Jung, JW; Kim, HR; Kim, YS; Kwon, SJ; Oh, SH; Park, DS; Yoon, KH, 2015)
" The aim of this study is to investigate the effects of combined autophagy inhibitor 3-methyladenine (3-MA) on the radiosensitivity of human adenocarcinoma A549 cells in hypoxia condition."3.78[The effect of autophagy on the radioresistance of human adenocarcinoma A549 cell in hypoxia condition]. ( Cai, A; Li, L; Li, Y; Xu, L; Zhong, X, 2012)
"Trimetrexate (150 mg/m2) was administered intravenously over 30 minutes every 2 weeks."2.67A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group. ( Ebbert, LP; Foley, JF; Gesme, DH; Hatfield, AK; Jett, JR; Krook, JE; Mailliard, JA; Maksymiuk, AW; Schreffler, DD; Su, JQ, 1993)
"CAFs contribute to metastasis process through direct or indirect interaction with tumor cells; however, the underlying mechanism is largely unknown."1.62Autophagic secretion of HMGB1 from cancer-associated fibroblasts promotes metastatic potential of non-small cell lung cancer cells via NFκB signaling. ( Cao, L; Chen, M; Furlong, F; Guo, X; Li, X; Meng, Z; Ren, Y; Wang, L; Wu, X; Xu, K; Zhang, Q; Zheng, S, 2021)
"Lung cancer has surpassed breast cancer as the leading cause of cancer death in females in developed countries and the leading cause of cancer death in males."1.62ALKBH1 promotes lung cancer by regulating m6A RNA demethylation. ( Gong, L; Guo, Y; Li, H; Liu, R; Liu, Z; Wang, C; Xie, W; Yu, Q; Zhang, Y, 2021)
"Camptothecin (CPT) is a well-known anticancer drug, which causes cancer cell apoptosis via the induction of DNA damage; however, the cytotoxicity of CPT easily reaches a plateau at a relatively high dose in lung cancer cells, thus limiting its efficacy."1.48Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy. ( Chen, BH; Chen, JY; Chiu, CC; Chiu, YH; Hsu, HW; Hsu, SH; Huang, KC; Huang, WP; Liu, W; Wu, CY, 2018)
"Colchicine is a well-known and potent microtubule targeting agent, but the therapeutic value of colchicine against cancer is limited by its toxicity against normal cells."1.43Colchicine induces autophagy and senescence in lung cancer cells at clinically admissible concentration: potential use of colchicine in combination with autophagy inhibitor in cancer therapy. ( Bhattacharya, S; Chakrabarti, G; Das, A; Datta, S; Ganguli, A, 2016)
" The aim of this study is to investigate the synergistic anticancer effect of resveratrol in combination with cisplatin and the potential anticancer mechanisms involved in A549 cells."1.43The synergistic effect of resveratrol in combination with cisplatin on apoptosis via modulating autophagy in A549 cells. ( Hu, S; Kong, H; Li, X; Wang, H; Xie, W; Xu, R; Ye, L; Zeng, X, 2016)
" Both TBQ and TBE are cytotoxic, but their toxic mechanisms have not been fully characterized."1.42Protective roles of aldo-keto reductase 1B10 and autophagy against toxicity induced by p-quinone metabolites of tert-butylhydroquinone in lung cancer A549 cells. ( Bunai, Y; Chen, H; El-Kabbani, O; Endo, S; Hara, A; Ikari, A; Matsunaga, T; Nishiyama, A; Soda, M; Suyama, M; Tajima, K; Takemura, M, 2015)
"The majority of chemotherapy treatments for lung cancer use cisplatin; however, its use is limited as it has several side-effects."1.40Autophagy induction by low-dose cisplatin: the role of p53 in autophagy. ( Cho, KH; Kwon, KB; Lee, KK; Lee, SY; Lee, YR; Moon, SR; Park, JH; So, HS; Yang, SH, 2014)
"3-Nitrobenzanthrone (3-NBA) is a potent mutagen and potential human carcinogen identified in diesel exhaust and ambient air particulate matter."1.33Identification of three major DNA adducts formed by the carcinogenic air pollutant 3-nitrobenzanthrone in rat lung at the C8 and N2 position of guanine and at the N6 position of adenine. ( Arlt, VM; Kanno, T; Kawanishi, M; Osborne, MR; Phillips, DH; Schmeiser, HH; Takamura-Enya, T; Yagi, T, 2006)
" With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer."1.28Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer. ( Berger, MZ; Dimaggio, JJ; Gralla, RJ; Heelan, RT; Kris, MG; Marks, LD; Potanovich, LM, 1991)

Research

Studies (78)

TimeframeStudies, this research(%)All Research%
pre-19905 (6.41)18.7374
1990's8 (10.26)18.2507
2000's8 (10.26)29.6817
2010's45 (57.69)24.3611
2020's12 (15.38)2.80

Authors

AuthorsStudies
Ren, Y1
Cao, L2
Wang, L9
Zheng, S3
Zhang, Q6
Guo, X1
Li, X10
Chen, M1
Wu, X3
Furlong, F1
Meng, Z1
Xu, K1
Qu, J2
Jiang, M1
Wei, Z1
Fu, G1
Zhang, X8
Li, L6
Li, Z4
Lu, C2
Li, J9
Zhang, K1
Lin, C1
Tang, X1
Liu, Z6
Zhang, Y10
Han, R2
Wang, Y11
Feng, M1
Zhuang, Y1
Hu, C3
He, Y3
Melville, P1
Mohammed, F1
RuiWen Kuo, C1
Bradley, J1
Preston, G1
Dempsey, OJ1
Chung, LY1
Tang, SJ2
Wu, YC1
Yang, KC1
Huang, HJ2
Sun, GH1
Sun, KH1
Zhou, H3
Yang, L1
Dang, Q1
Huang, J4
Cheng, Y1
Shi, W1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y4
Wang, J9
Huang, L2
Hu, K2
Liu, H4
Wang, H4
Guo, Z2
Song, Y1
Huang, H5
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S2
Cheng, T1
Zhou, X2
Wang, B7
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W4
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X6
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J7
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J3
Jiang, H2
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X3
Yang, M2
Yang, Q2
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L4
Yang, X2
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H5
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C6
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Hu, Z1
You, Q2
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Du, S1
Cui, J1
Wu, W1
Liu, Y8
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H2
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G3
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D2
Ma, L1
Hu, T1
Wang, F2
Han, Z1
Yin, Z1
Ge, X2
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y5
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y7
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J5
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F2
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J3
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q2
Zhou, C1
Liu, C2
Liu, W2
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y2
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X4
Cao, Q1
Yuan, X1
Nie, W1
Yang, J3
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L5
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N2
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q4
Liu, X4
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R2
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B2
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH3
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y2
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Liang, H1
Xu, X2
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J2
Gu, C1
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X2
Zhou, Y3
Xue, H1
Zhang, W4
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J3
Cai, S1
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L2
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y2
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J2
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S2
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P2
Sun, YH1
Zhang, HB1
Gu, J2
Zhu, Q1
Chen, Y3
Ge, D1
Liu, R1
Gong, L1
Xie, W2
Hao, CC1
Xu, CY1
Zhao, XY1
Luo, JN1
Wang, G1
Zhao, LH1
Ge, XF1
Shulman, K1
Kazarin, O1
Tannous, E1
Sofer, O1
Ghaddar, N1
Wang, S1
Woodvine, B1
Krishnamoorthy, J1
van Hoef, V1
Darini, C1
Kazimierczak, U1
Ah-Son, N1
Popper, H1
Johnson, M1
Officer, L1
Teodósio, A1
Broggini, M1
Mann, KK1
Hatzoglou, M1
Topisirovic, I1
Larsson, O1
Le Quesne, J1
Koromilas, AE1
Shan, M1
Qin, J1
Jin, F1
Guan, H1
Su, Q1
Cheng, K1
Hosoya, T1
Sato-Kaneko, F1
Ahmadi, A1
Yao, S1
Lao, F1
Kitaura, K1
Matsutani, T1
Carson, DA1
Hayashi, T1
Aldana, G1
Jimenez, CA1
Moran, C1
Chiu, YH1
Hsu, SH1
Hsu, HW1
Huang, KC1
Wu, CY1
Huang, WP1
Chen, JY1
Chen, BH1
Chiu, CC1
Zhu, R1
Xue, X1
Shen, M1
Chen, F1
Tsai, Y1
Keng, PC1
Lee, SO1
Yan, Y1
Hu, R1
Lin, N1
Yang, CL1
Zhao, ZJ1
Zuo, XX1
Liang, TS1
Ma, SL1
Yang, DK1
Al-Toubah, T1
Schell, MJ1
Cives, M1
Zhou, JM1
Soares, HP1
Strosberg, JR1
Uekita, T1
Fujii, S1
Miyazawa, Y1
Hashiguchi, A1
Abe, H1
Sakamoto, M1
Sakai, R1
Hu, CW1
Lee, H1
Chen, JL1
Li, YJ1
Chao, MR1
Liu, JH1
Chai, K1
Tashiro, S1
Onodera, S1
Ikejima, T1
Zhao, YX1
Cheng, C1
Zhu, F1
Wu, HG1
Ren, JH1
Chen, WH1
Hsieh, MJ1
Lin, CW1
Yang, SF1
Sheu, GT1
Yu, YY1
Chen, MK1
Chiou, HL1
Cho, KH1
Kwon, KB2
Lee, YR2
So, HS2
Lee, KK2
Lee, SY2
Moon, SR2
Yang, SH2
Jo, HJ1
Lee, S1
Jeong, K1
Jiang, RY1
Pei, HL1
Gu, WD1
Wang, ZG1
Gao, W1
Wang, M1
Lu, H1
Dai, B1
Ou, Z1
Heymach, JV1
Gold, KA1
Minna, J1
Roth, JA1
Hofstetter, WL1
Swisher, SG1
Fang, B1
Haura, EB1
Rix, U1
Endo, S1
Nishiyama, A1
Suyama, M1
Takemura, M1
Soda, M1
Chen, H2
Tajima, K1
El-Kabbani, O1
Bunai, Y1
Hara, A1
Matsunaga, T1
Ikari, A1
Zhao, H1
You, J1
Jing, F1
Tang, MC1
Wu, MY1
Hwang, MH1
Chang, YT1
Lin, AM1
Yang, JC1
Cummings, CT1
Davies, KD1
Kirkpatrick, GD1
Zhang, D1
DeRyckere, D1
Frye, SV1
Earp, HS1
Graham, DK1
Ruan, Y1
Mao, Y1
Hua, D1
Cai, D1
Hwang, KE1
Kim, YS1
Jung, JW1
Kwon, SJ1
Park, DS1
Cha, BK1
Oh, SH1
Yoon, KH1
Jeong, ET1
Kim, HR1
Wu, H2
Wang, A2
Chen, C2
Ye, Z2
Zhao, Z2
Yu, K1
Yan, XE2
Zhao, P2
Weisberg, EL2
Gray, NS2
Yun, CH2
Bhattacharya, S1
Das, A1
Datta, S1
Ganguli, A1
Chakrabarti, G1
Tan, P1
Yan, B1
Zhao, J2
Guo, J1
Ma, Z1
Hu, S1
Xu, R1
Ye, L1
Kong, H1
Zeng, X1
Khashab, T1
Loghavi, S1
Konoplev, SN1
Samaniego, F1
Xie, Q1
Jin, H1
Che, X1
Huang, C2
Chen, LC1
Gao, J1
Xie, WY1
Zhou, XD1
Chen, LX1
Ran, DH1
Li, M2
Xie, S1
Gan, G1
Cao, Y1
Zhu, D1
Han, H1
Ye, M1
Mi, J1
Mercier, C1
Dahan, L1
Ouafik, L1
André, N1
Ciccolini, J1
Basu, I1
Locker, J1
Cassera, MB1
Belbin, TJ1
Merino, EF1
Hemeon, I1
Evans, GB1
Guha, C1
Schramm, VL1
Hsin, IL1
Ou, CC1
Wu, TC1
Jan, MS1
Wu, MF1
Chiu, LY1
Lue, KH1
Ko, JL1
Ling, YH1
Aracil, M1
Zou, Y1
Yuan, Z1
Lu, B1
Jimeno, J1
Cuervo, AM1
Perez-Soler, R1
Sirichanchuen, B1
Pengsuparp, T1
Chanvorachote, P1
Arakawa, H1
Weng, MW1
Chen, WC1
Tang, MS1
Han, L1
Yang, H1
Duan, L1
Zhou, B1
Ma, R1
Cai, A1
Zhong, X1
Rodin, SN1
Rodin, AS1
Cohen, Y1
Xing, M1
Mambo, E1
Trink, B1
Beller, U1
Westra, WH1
Ladenson, PW1
Sidransky, D2
Casse, C1
Hu, YC1
Ahrendt, SA1
Speina, E1
Zielińska, M1
Barbin, A1
Gackowski, D1
Kowalewski, J1
Graziewicz, MA1
Siedlecki, JA1
Oliński, R1
Tudek, B1
ROGERS, S1
TRAININ, N1
KAYE, AM1
BERENBLUM, I1
COSTAKEL, O1
Qian, X1
Arlt, VM1
Schmeiser, HH1
Osborne, MR1
Kawanishi, M1
Kanno, T1
Yagi, T1
Phillips, DH1
Takamura-Enya, T1
Wang, YJ1
Ho, YS1
Lo, MJ1
Lin, JK1
Ronai, ZA1
Gradia, S1
Peterson, LA1
Hecht, SS1
Zhu, W1
Roma, P1
Pellegatta, F1
Catapano, AL1
Gesme, DH1
Jett, JR1
Schreffler, DD1
Su, JQ1
Mailliard, JA1
Foley, JF1
Krook, JE1
Maksymiuk, AW1
Hatfield, AK1
Ebbert, LP1
Chang, AY1
Tu, ZN1
Smith, JL1
Bonomi, P1
Smith, TJ1
Wiernik, PH1
Blum, R1
Barciszewski, J1
Mielcarek, M1
Stobiecki, M1
Siboska, G1
Clark, BF1
Fisher, MJ1
Virmani, AK1
Wu, L1
Aplenc, R1
Harper, JC1
Powell, SM1
Rebbeck, TR1
Gazdar, AF1
El-Deiry, WS1
Berger, MZ1
Kris, MG1
Gralla, RJ1
Marks, LD1
Potanovich, LM1
Dimaggio, JJ1
Heelan, RT1
Barbieri, R1
Ruisi, G1
Atassi, G1
Evans, WK1
Eisenhauer, EA1
Cormier, Y1
Ayoub, J1
Wierzbicki, R1
Laberge, F1
Shepherd, FA1
Saez, R1
Craig, JB1
Kuhn, JG1
Weiss, GR1
Koeller, J1
Phillips, J1
Havlin, K1
Harman, G1
Hardy, J1
Melink, TJ1
Frei, JV1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors With Biologic and Proteomic Analysis[NCT00095459]Phase 157 participants (Actual)Interventional2004-11-02Completed
A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer[NCT00436215]Phase 255 participants (Actual)Interventional2006-12-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00436215)
Timeframe: up to 28 months

InterventionParticipants (Count of Participants)
BAY 43-9006 + Bevacizumab54

Progression-free Survival

Progression free survival is defined by the number of weeks between the first day of treatment and the date of cancer progression. (NCT00436215)
Timeframe: up to 28 months

InterventionWeeks (Mean)
BAY 43-9006 + Bevacizumab26

Clinical Response Rate.

Clinical response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease (PD) is a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started lasting at least 6 months. (NCT00436215)
Timeframe: patients were followed for a median of 18 weeks (range 1-116 weeks)

Interventionpercentage of participants (Number)
Complete ResponsePartial ResponseProgressive DiseaseStable Disease
BAY 43-9006 + Bevacizumab0192160

Reviews

3 reviews available for adenine and Cancer of Lung

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Association between interleukin-8 -251A/T polymorphism and risk of lung cancer: a meta-analysis.
    Cancer investigation, 2014, Volume: 32, Issue:10

    Topics: Adenine; Asian People; Computational Biology; Databases, Bibliographic; Genetic Association Studies;

2014
Inhibition of autophagy enhances heat-induced apoptosis in human non-small cell lung cancer cells through ER stress pathways.
    Archives of biochemistry and biophysics, 2016, 10-01, Volume: 607

    Topics: A549 Cells; Adenine; Animals; Apoptosis; Autophagy; Beclin-1; Carcinoma, Non-Small-Cell Lung; Cell L

2016

Trials

5 trials available for adenine and Cancer of Lung

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms.
    Neuroendocrinology, 2020, Volume: 110, Issue:5

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Carcinoid Tumor; Female; Gastrointestinal

2020
A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.
    Cancer, 1993, May-01, Volume: 71, Issue:9

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug

1993
Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588).
    Investigational new drugs, 1995, Volume: 13, Issue:2

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drugs, Investigational;

1995
Phase I clinical investigation of amonafide.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:9

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pr

1989

Other Studies

71 other studies available for adenine and Cancer of Lung

ArticleYear
Autophagic secretion of HMGB1 from cancer-associated fibroblasts promotes metastatic potential of non-small cell lung cancer cells via NFκB signaling.
    Cell death & disease, 2021, 09-22, Volume: 12, Issue:10

    Topics: Adenine; Autophagy; Autophagy-Related Protein 5; Cancer-Associated Fibroblasts; Carcinoma, Non-Small

2021
Survival-associated N
    BMC cancer, 2021, Nov-24, Volume: 21, Issue:1

    Topics: Adenine; Adenosine; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Databases, Genet

2021
Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.
    Communications biology, 2022, 02-23, Volume: 5, Issue:1

    Topics: Acrylamides; Adenine; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm;

2022
Nodules, nodes and non-functioning macrophages: A risk with ibrutinib therapy.
    The journal of the Royal College of Physicians of Edinburgh, 2022, Volume: 52, Issue:1

    Topics: Adenine; Aged; Antifungal Agents; Bronchoscopy; Humans; Lung Neoplasms; Macrophages; Male; Mediastin

2022
Platinum-based combination chemotherapy triggers cancer cell death through induction of BNIP3 and ROS, but not autophagy.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:2

    Topics: A549 Cells; Adenine; Antineoplastic Agents; Autophagy; Cell Death; Drug Therapy, Combination; Humans

2020
Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.
    Cancer biology & therapy, 2020, 04-02, Volume: 21, Issue:4

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosp

2020
Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma.
    Briefings in bioinformatics, 2021, 07-20, Volume: 22, Issue:4

    Topics: Adenine; Adenocarcinoma of Lung; Databases, Nucleic Acid; Female; Gene Expression Regulation, Neopla

2021
ALKBH1 promotes lung cancer by regulating m6A RNA demethylation.
    Biochemical pharmacology, 2021, Volume: 189

    Topics: A549 Cells; Adenine; AlkB Homolog 1, Histone H2a Dioxygenase; Amino Acid Sequence; Animals; Demethyl

2021
Up-regulation of VANGL1 by IGF2BPs and miR-29b-3p attenuates the detrimental effect of irradiation on lung adenocarcinoma.
    Journal of experimental & clinical cancer research : CR, 2020, Nov-23, Volume: 39, Issue:1

    Topics: Adenine; Adenocarcinoma of Lung; Adult; Aged; Carrier Proteins; DNA Damage; Humans; Insulin-Like Gro

2020
Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma.
    The Israel Medical Association journal : IMAJ, 2021, Volume: 23, Issue:6

    Topics: Adenine; Adenocarcinoma of Lung; Aged; ErbB Receptors; Humans; Leukemia, Lymphocytic, Chronic, B-Cel

2021
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer.
    Nature communications, 2021, 07-30, Volume: 12, Issue:1

    Topics: Adenine; Adenocarcinoma; Animals; Carcinogenesis; Cell Line, Tumor; Dual Specificity Phosphatase 6;

2021
Autophagy suppresses isoprenaline-induced M2 macrophage polarization via the ROS/ERK and mTOR signaling pathway.
    Free radical biology & medicine, 2017, Volume: 110

    Topics: Adenine; Animals; Antibiotics, Antineoplastic; Autophagy; Cell Line, Tumor; Epithelial Cells; Female

2017
[Inhibition of autophagy initiation stage enhances camptothecin-induced apoptosis in NCI-H1975 cells].
    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2017, Volume: 33, Issue:12

    Topics: Adenine; Apoptosis; Autophagy; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell

2017
Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
    Proceedings of the National Academy of Sciences of the United States of America, 2018, 07-17, Volume: 115, Issue:29

    Topics: Adenine; Administration, Intranasal; Animals; CD8-Positive T-Lymphocytes; Female; Immunity, Cellular

2018
Unusual cause of sinusitis and cough.
    BMJ case reports, 2018, Jul-19, Volume: 2018

    Topics: Adenine; Biopsy; Cough; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Midd

2018
Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy.
    International journal of oncology, 2018, Volume: 53, Issue:5

    Topics: Adenine; Amino Acid Chloromethyl Ketones; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

2018
RETRACTED: Neuroendocrine differentiation contributes to radioresistance development and metastatic potential increase in non-small cell lung cancer.
    Biochimica et biophysica acta. Molecular cell research, 2018, Volume: 1865, Issue:12

    Topics: A549 Cells; Adenine; Animals; Antibodies, Neutralizing; Biomarkers, Tumor; Carcinoma, Non-Small-Cell

2018
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
    Molecular oncology, 2019, Volume: 13, Issue:4

    Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Bridged Bicyclo Compounds, Heteroc

2019
Microwave hyperthermia enhances the sensitivity of lung cancer cells to gemcitabine through reactive oxygen species‑induced autophagic death.
    Oncology reports, 2019, Volume: 41, Issue:5

    Topics: Adenine; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Deo

2019
Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells.
    Cancer science, 2013, Volume: 104, Issue:7

    Topics: Adenine; Adenocarcinoma; Adenocarcinoma of Lung; Anoikis; Antigens, CD; Antigens, Neoplasm; Autophag

2013
Two drugs deemed breakthrough therapies.
    Cancer discovery, 2013, Volume: 3, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Car

2013
Optimization of global DNA methylation measurement by LC-MS/MS and its application in lung cancer patients.
    Analytical and bioanalytical chemistry, 2013, Volume: 405, Issue:27

    Topics: Adenine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Chromatography, Liquid; Deoxycytidine; DNA

2013
Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells.
    The Journal of pharmacy and pharmacology, 2013, Volume: 65, Issue:11

    Topics: Adenine; Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autop

2013
Suppression of low-dose hyper-radiosensitivity in human lung cancer cell line A549 by radiation-induced autophagy.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2013, Volume: 33, Issue:5

    Topics: Adenine; Autophagy; Blotting, Western; Cell Line, Tumor; Cell Survival; Dose-Response Relationship,

2013
A combination of pterostilbene with autophagy inhibitors exerts efficient apoptotic characteristics in both chemosensitive and chemoresistant lung cancer cells.
    Toxicological sciences : an official journal of the Society of Toxicology, 2014, Volume: 137, Issue:1

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; A

2014
Autophagy induction by low-dose cisplatin: the role of p53 in autophagy.
    Oncology reports, 2014, Volume: 31, Issue:1

    Topics: Adenine; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Cisplatin; Ge

2014
The role of autophagy induced by pemetrexed in lung adenocarcinoma cells.
    Oncology reports, 2014, Volume: 31, Issue:5

    Topics: Adenine; Adenocarcinoma; Adenocarcinoma of Lung; Annexin A5; Antimetabolites, Antineoplastic; Apopto

2014
Autophagic inhibitor attenuates rapamycin-induced inhibition of proliferation in cultured A549 lung cancer cells.
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:6

    Topics: Adenine; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Caspase 3; Cell Death; Cell Line, Tumor

2014
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:9

    Topics: Adenine; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Lin

2014
Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:9

    Topics: Adenine; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lun

2014
Protective roles of aldo-keto reductase 1B10 and autophagy against toxicity induced by p-quinone metabolites of tert-butylhydroquinone in lung cancer A549 cells.
    Chemico-biological interactions, 2015, Jun-05, Volume: 234

    Topics: Adenine; Aldehyde Reductase; Aldo-Keto Reductases; Antioxidants; Autophagy; Benzoquinones; Caspase 3

2015
Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Adenine; Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chloroq

2015
Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:9

    Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; c-Mer Tyrosine Kinase; Carcinoma, Non-Small-Cell

2015
Autophagy inhibition enhances isorhamnetin‑induced mitochondria‑dependent apoptosis in non‑small cell lung cancer cells.
    Molecular medicine reports, 2015, Volume: 12, Issue:4

    Topics: Adenine; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell

2015
Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway.
    International journal of immunopathology and pharmacology, 2015, Volume: 28, Issue:3

    Topics: A549 Cells; Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Pr

2015
Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.
    Oncotarget, 2015, Oct-06, Volume: 6, Issue:30

    Topics: Adenine; AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apo

2015
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.
    Oncotarget, 2015, Oct-13, Volume: 6, Issue:31

    Topics: Adenine; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Pro

2015
Colchicine induces autophagy and senescence in lung cancer cells at clinically admissible concentration: potential use of colchicine in combination with autophagy inhibitor in cancer therapy.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:8

    Topics: A549 Cells; Adenine; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Cycle; Cell Line;

2016
ER stress and autophagy are involved in the apoptosis induced by cisplatin in human lung cancer cells.
    Oncology reports, 2016, Volume: 35, Issue:5

    Topics: A549 Cells; Adenine; Antineoplastic Agents; Apoptosis; Autophagy; Cell Proliferation; Chloroquine; C

2016
The synergistic effect of resveratrol in combination with cisplatin on apoptosis via modulating autophagy in A549 cells.
    Acta biochimica et biophysica Sinica, 2016, Volume: 48, Issue:6

    Topics: A549 Cells; Adenine; Adenocarcinoma, Bronchiolo-Alveolar; Apoptosis; Autophagosomes; Autophagy; Cisp

2016
Resolution of lung adenocarcinoma after discontinuation of ibrutinib.
    BMJ case reports, 2016, Jul-18, Volume: 2016

    Topics: Adenine; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Humans; Lung; Lung Neoplasms; Male; Piperidin

2016
Upregulation of SQSTM1/p62 contributes to nickel-induced malignant transformation of human bronchial epithelial cells.
    Autophagy, 2016, 10-02, Volume: 12, Issue:10

    Topics: Adenine; Animals; Autophagy; Autophagy-Related Protein-1 Homolog; Beclin-1; Bronchi; Cell Line, Tumo

2016
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.
    Oncotarget, 2016, Oct-25, Volume: 7, Issue:43

    Topics: Acrylamides; Adenine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Humans; Lung

2016
Synthesis and evaluation of novel amonafide-polyamine conjugates as anticancer agents.
    Chemical biology & drug design, 2017, Volume: 89, Issue:5

    Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug S

2017
Cancer-associated Fibroblasts Promote Irradiated Cancer Cell Recovery Through Autophagy.
    EBioMedicine, 2017, Volume: 17

    Topics: 3-Hydroxybutyric Acid; Adenine; Aged; Aged, 80 and over; Animals; Autophagy; Cell Line, Tumor; Cells

2017
Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:9

    Topics: Adenine; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Confounding Factors, Epide

2010
Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase.
    The Journal of biological chemistry, 2011, Feb-11, Volume: 286, Issue:6

    Topics: Adenine; Adenosine; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor

2011
GMI, an immunomodulatory protein from Ganoderma microsporum, induces autophagy in non-small cell lung cancer cells.
    Autophagy, 2011, Volume: 7, Issue:8

    Topics: Adenine; Animals; Apoptosis; Autophagy; Calcium; Carcinoma, Non-Small-Cell Lung; Cell Proliferation;

2011
PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-15, Volume: 17, Issue:16

    Topics: Adenine; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5;

2011
Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells.
    Molecular and cellular biochemistry, 2012, Volume: 364, Issue:1-2

    Topics: Adenine; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Class II

2012
Chromium (VI) induces both bulky DNA adducts and oxidative DNA damage at adenines and guanines in the p53 gene of human lung cells.
    Carcinogenesis, 2012, Volume: 33, Issue:10

    Topics: Adenine; Adenocarcinoma; Carcinogens, Environmental; Cell Line, Tumor; Chromium; DNA Adducts; DNA Da

2012
The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 79, Issue:1

    Topics: Adenine; Adult; Alleles; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological

2013
[The effect of autophagy on the radioresistance of human adenocarcinoma A549 cell in hypoxia condition].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:11

    Topics: Adenine; Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Cell Hypoxia; Cell Line, Tumor; Gamma Ra

2012
On the origin of p53 G:C --> T:A transversions in lung cancers.
    Mutation research, 2002, Oct-31, Volume: 508, Issue:1-2

    Topics: Adenine; Chi-Square Distribution; Databases, Genetic; DNA Repair; Gene Frequency; Humans; Lung Neopl

2002
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
The XRCC1 codon 399 Gln allele is associated with adenine to guanine p53 mutations in non-small cell lung cancer.
    Mutation research, 2003, Jul-25, Volume: 528, Issue:1-2

    Topics: Adenine; Alleles; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Female; Genes, p53; Genotype

2003
Decreased repair activities of 1,N(6)-ethenoadenine and 3,N(4)-ethenocytosine in lung adenocarcinoma patients.
    Cancer research, 2003, Aug-01, Volume: 63, Issue:15

    Topics: Adenine; Adenocarcinoma; Adult; Age Factors; Aged; Cytosine; DNA Adducts; DNA Repair; DNA, Neoplasm;

2003
Studies of the mechanism of action of urethane in initiating pulmonary adenomas in mice. II. Its relation to nucleic acid synthesis.
    The Journal of experimental medicine, 1957, Apr-01, Volume: 105, Issue:4

    Topics: Adenine; Adenoma; Animals; DNA; Lung Neoplasms; Mice; Neoplasms; Nucleic Acids; Orotic Acid; Pyrimid

1957
INFLUENCE OF MUTAGENS ON THE INITIATION OF SKIN CARCINOGENESIS.
    Biochemical pharmacology, 1964, Volume: 13

    Topics: 2-Aminopurine; Acridines; Adenine; Carcinogenesis; Carcinogens; Idoxuridine; Lung Neoplasms; Mice; M

1964
THE CHEMOTHERAPY OF CANCER WITH MASSIVE DOSES UNDER THE PROTECTION OF PERFUSION OF AUTOGENOUS HEMATOPOIETIC TISSUE.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Adenine; Bone Marrow Transplantation; Breast Neoplasms; DNA; Female; Folic Acid; Humans; Lung Neopla

1964
Novel thiazonaphthalimides as efficient antitumor and DNA photocleaving agents: effects of intercalation, side chains, and substituent groups.
    Bioorganic & medicinal chemistry, 2005, Aug-15, Volume: 13, Issue:16

    Topics: Adenine; Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; DNA; DNA, Superhelical; Drug Scre

2005
Identification of three major DNA adducts formed by the carcinogenic air pollutant 3-nitrobenzanthrone in rat lung at the C8 and N2 position of guanine and at the N6 position of adenine.
    International journal of cancer, 2006, May-01, Volume: 118, Issue:9

    Topics: Adenine; Animals; Benz(a)Anthracenes; DNA Adducts; Female; Guanine; Lung; Lung Neoplasms; Phosphorus

2006
Oxidative modification of DNA bases in rat liver and lung during chemical carcinogenesis and aging.
    Chemico-biological interactions, 1995, Volume: 94, Issue:2

    Topics: 2-Acetylaminofluorene; Adenine; Aging; Animals; Antineoplastic Agents; Disease Models, Animal; DNA D

1995
G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents.
    Carcinogenesis, 1993, Volume: 14, Issue:11

    Topics: Adenine; Animals; Base Sequence; Carcinogens; Codon; Dimethylnitrosamine; DNA, Neoplasm; Female; Gen

1993
Oxidized-LDL induce the expression of heat shock protein 70 in human endothelial cells.
    Biochemical and biophysical research communications, 1994, Apr-15, Volume: 200, Issue:1

    Topics: Adenine; Cell Count; Cells, Cultured; Endothelium, Vascular; Heat-Shock Proteins; Humans; Hybrid Cel

1994
Identification of 6-furfuryladenine (kinetin) in human urine.
    Biochemical and biophysical research communications, 2000, Dec-09, Volume: 279, Issue:1

    Topics: Adenine; Case-Control Studies; Gas Chromatography-Mass Spectrometry; Humans; Kinetin; Lung Neoplasms

2000
Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:6

    Topics: Adenine; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Alleles; Amino Acid Sequence;

2001
Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
    American journal of clinical oncology, 1991, Volume: 14, Issue:2

    Topics: Adenine; Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluatio

1991
The antitumor activity and the structure of bis(adeninato-N9) diphenyltin(IV).
    Journal of inorganic biochemistry, 1991, Volume: 41, Issue:1

    Topics: Adenine; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Colonic Neoplasms; Female; Hum

1991
Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:3

    Topics: Adenine; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Protocols; Drug Evaluation; Dr

1990
Tissue-dependent differences in DNA methylation products of mice treated with methyl-labelled methylnitrosourea.
    International journal of cancer, 1971, May-15, Volume: 7, Issue:3

    Topics: Adenine; Adenoma; Animals; Bone Marrow; Carbon Isotopes; DNA, Neoplasm; Guanine; Kidney; Liver; Lung

1971